14,290 Shares in Moderna, Inc. $MRNA Acquired by LVM Capital Management Ltd. MI

LVM Capital Management Ltd. MI purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 14,290 shares of the company’s stock, valued at approximately $421,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. MUFG Securities EMEA plc purchased a new stake in shares of Moderna during the 2nd quarter worth approximately $28,000. Ameriflex Group Inc. grew its position in shares of Moderna by 3,775.0% in the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock valued at $32,000 after buying an additional 1,208 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in Moderna by 148.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after acquiring an additional 801 shares in the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new stake in Moderna during the 3rd quarter worth $43,000. Finally, CVA Family Office LLC lifted its position in Moderna by 1,229.7% in the fourth quarter. CVA Family Office LLC now owns 1,476 shares of the company’s stock valued at $44,000 after acquiring an additional 1,365 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Moderna news, President Stephen Hoge sold 160,009 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the completion of the sale, the president directly owned 1,457,427 shares of the company’s stock, valued at $71,180,734.68. This represents a 9.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.80% of the stock is currently owned by corporate insiders.

Moderna Trading Up 4.3%

NASDAQ MRNA opened at $53.54 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.22 and a current ratio of 3.29. The firm has a market cap of $21.15 billion, a PE ratio of -7.36 and a beta of 1.29. Moderna, Inc. has a one year low of $22.28 and a one year high of $59.55. The firm’s fifty day moving average is $48.22 and its two-hundred day moving average is $34.82.

Moderna (NASDAQ:MRNA) last announced its earnings results on Friday, February 13th. The company reported ($2.11) EPS for the quarter, beating analysts’ consensus estimates of ($2.79) by $0.68. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. The business had revenue of $678.00 million during the quarter, compared to analysts’ expectations of $611.14 million. During the same period in the prior year, the company earned ($2.91) earnings per share. The business’s revenue was down 33.2% compared to the same quarter last year. Analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on MRNA shares. Morgan Stanley set a $30.00 price objective on shares of Moderna in a research note on Monday, February 16th. Barclays initiated coverage on Moderna in a report on Wednesday, January 28th. They issued an “equal weight” rating and a $25.00 target price for the company. The Goldman Sachs Group upped their target price on Moderna from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Tuesday, February 17th. Jefferies Financial Group set a $37.00 price target on Moderna and gave the stock a “hold” rating in a research note on Tuesday, March 3rd. Finally, TD Cowen reiterated a “hold” rating on shares of Moderna in a research note on Thursday, January 29th. Two investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and five have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus target price of $32.33.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.